Results 91 to 100 of about 14,972 (184)

Gene- and subtype-dependent prognostic impact of ras pathway mutations in acute myeloid leukemia: a cohort study of 2,500 patients. [PDF]

Blood Cancer J
Shen H, Hui Y, Liu Y, Li S, Lin D, Fang Q, Wang Y, Gong B, Zhou C, Liu K, Zhang G, Gong X, Qiu S, Liu B, Wang Y, Mi Y, Li Y, Wang J, Wei H.   +18 more
europepmc   +1 more source

RETRACTED: Richards et al. Protein Tyrosine Phosphatase Non-Receptor 11 (<i>PTPN11</i>/Shp2) as a Driver Oncogene and a Novel Therapeutic Target in Non-Small Cell Lung Cancer (NSCLC). <i>Int. J. Mol. Sci.</i> 2023, <i>24</i>, 10545. [PDF]

Int J Mol Sci
Richards CE, Elamin YY, Carr A, Gately K, Rafee S, Cremona M, Hanrahan E, Smyth R, Ryan D, Morgan RK, Kennedy S, Hudson L, Fay J, O'Byrne K, Hennessy BT, Toomey S.   +15 more
europepmc   +1 more source

Characterization of the clonal hierarchy and immunophenotype of PTPN11 mutations in acute myeloid leukemia. [PDF]

JCI Insight
Fobare S, Sharpe C, Quinn K, Bryant K, Miles LA, Bowman RL, Cheney C, Furby C, Long M, Fyock K, Wronowski B, Lerma JR, Mrózek K, Nicolet D, Sesterhenn TM, Johnstone ME, Pan J, Rai SN, Pasare C, Zimmermann N, Yu WM, Qu CK, Carroll A, Stone R, Wang ES, Kolitz J, Powell B, Perentesis JP, Eisfeld AK, Hertlein E, Byrd JC.   +30 more
europepmc   +1 more source

Clinical phenotypes and cochlear implant outcomes in patients with PTPN11-associated noonan spectrum disorders: Insights from a genetically screened cohort. [PDF]

Eur Arch Otorhinolaryngol
Chen Z, Bi Q, Kang B, Liu S, Zhai Y, Li G, Lv Y, Liu Y, Liu J, Li Y, Yang W, Xu X, Li Y.   +12 more
europepmc   +1 more source

P081 | EVALUATION OF PTPN11 MUTATION SUBTYPES AND THEIR POTENTIAL IMPACT ON CLINICAL OUTCOMES: A SINGLE-CENTER EXPERIENCE.

Haematologica
Background: PTPN11mutations can be found in 1.5%–12% of AML cases. They have been reported to cluster mainly in the N-terminal Src homology region 2 (N-SH2) and phosphatase (PTP) domains.
F. Crupi, G. Ciolli, M. Piccini, B. Scappini, L. Fasano, E. Quinti, A. Pasquini, J. Caroprese, N. Bartalucci, A. Enderti, C. Maccari, G. Rotunno, L. Signori, P. Guglielmelli, A.M. Vannucchi, F. Mannelli   +15 more
doaj  

PTPN11-related Noonan syndrome predisposes to multifocal low-grade CNS tumors harboring FGFR1 variants. [PDF]

J Neurooncol
Kohanbash G, Ryall S, Gary SE, Hoffman LM, Siddaway R, Bendel AE, Gripp KW, Walter AW, Hansford JR, Smith AA, Wang H, Skaugen JM, Tabori U, Hawkins CE, Broniscer A.   +14 more
europepmc   +1 more source

Largely preserved vestibular function despite severe-to-profound hearing loss in Noonan syndrome spectrum disorders. [PDF]

Eur Arch Otorhinolaryngol
Koda K, Ichijo K, Kamogashira T, Kinoshita M, Oka M, Kondo K, Fujimoto C.   +6 more
europepmc   +1 more source

Teasing apart the multiple roles of Shp2 (Ptpn11) in spermatogenesis

Asian Journal of Andrology, 2020
Maher, G, Goriely, A
openaire   +4 more sources

Targeting MCL-1 and MAPK overcomes venetoclax resistance in FLT3-ITD-positive AML cells harbouring activating PTPN11 (SHP-2) mutations. [PDF]

Br J Haematol
Fleischmann M, Hansen O, Voigtländer D, Bechwar J, Schwietzer LJ, Bahr S, Schnetzke U, Fischer M, Heidel FH, Schnöder TM, Müller JP, Hochhaus A, Scholl S.   +12 more
europepmc   +1 more source

Integration of Network Pharmacology, Molecular Docking, and Molecular Dynamics to Decipher the Multi-Target Mechanisms of Crocin I in Parkinson's Disease with In Vivo Validation. [PDF]

ACS Omega
Wang J, Lv M, Yu J, Xu Y, Lin Y, Pei J, Zhou M.   +6 more
europepmc   +1 more source